Navigation Links
Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer
Date:9/15/2008

ncer after failure of standard treatment, including Sutent(R) (sunitinib) or Nexavar(R) (sorafenib), or both.

Earlier this year, interim results from RECORD-1 presented at the American Society of Clinical Oncology Congress were used to submit regulatory applications for RAD001 as a treatment for metastatic renal cell carcinoma (RCC). RAD001 was granted priority review by the US Food and Drug Administration. FDA priority review status is granted to therapies that could potentially fill a currently unmet medical need and accelerates the standard review time from ten to six months.

"We are encouraged by the continued benefit RAD001 provided to patients with advanced kidney cancer in this trial," said David Epstein, CEO and President of Novartis Oncology. "Novartis is committed to bringing this new, innovative therapy to market and to exploring the potential of RAD001 beyond this specific treatment setting."

RAD001 is a once-daily oral therapy that may offer a new approach to cancer treatment by continuously inhibiting the mTOR protein, a central regulator of cell division and tumor blood vessel growth. Data suggest RAD001 has clinical activity as a single agent or in combination with other therapies in multiple types of cancer, including pancreatic neuroendocrine tumors, breast, gastric, lung and lymphoma.

RECORD-1 results

RECORD-1 is the largest Phase III clinical trial investigating the effects of an oral mTOR inhibitor in metastatic RCC. It is a randomized, double-blind, placebo-controlled multicenter trial of more than 400 patients with RCC whose cancer worsened despite prior treatment including Nexavar or Sutent, or both. In addition, prior therapy with Avastin, interferon and interleukin-2 was allowed.

The primary endpoint of RECORD-1 was progression-free survival (PFS) assessed via a blinded, independent central review and defined as the amount of time between randomization and first documented disease progression or dea
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cytels Clinical Innovation Experts Cyrus Mehta and Judith Quinlan Reveal Latest Adaptive Trial Successes at 44th Annual DIA Meeting
2. Latest Cell Publication Describes the Novel Kinase Regulators Using OriGenes Functional Kinome Collection
3. Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously
4. RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
5. RAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer
6. Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
7. RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
8. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
9. AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Alzheimers Disease
10. Most Cancer Treatment Studies Arent Published, Study Finds
11. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015  Amgen (NASDAQ: AMGN ... partner and managing director of Warburg Pincus LLC, to the ... to welcome Fred Hassan and the deep, global ... Board," said Robert A. Bradway , chairman and chief ... to innovation will serve Amgen well." Mr. Hassan ...
(Date:7/30/2015)...  Cleveland Clinic President Wael Barsoum , M.D. ... that industry is compelled to adopt declining reimbursements throughout ... develop the transformational innovations -- required to thrive in ... by Doug Kohrs , past President and CEO ... that industry must add "episode of care," also known ...
(Date:7/30/2015)... -- Growth of the U.S. nonprescription market is primarily driven ... to the OTC market. Due to an increasingly favorable ... activity over the next five years with several all ... entering the market into existing categories. If ... those with low to moderate likelihood), the market is ...
Breaking Medicine Technology:Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... Aug. 4 Biomoda, Inc. (OTC,Bulletin Board: BMOD) ... submitted to the FDA a pre-IDE (Investigational Device,Exemption) ... assay,for detection of early lung cancer in veterans. ... million over two years towards the,study that will ...
... Rx, a specialty,pharmaceutical company leveraging its proprietary ... products, today announced the,completion of pilot product ... oxalate, a selective serotonin reuptake inhibitor.,Escitalopram oxalate ... and is marketed under the brand name ...
Cached Medicine Technology:FDA Reviewing Biomoda Submission for Cancer Screening Study 2MonoSol Rx Completes Thin Film Escitalopram Oxalate Pilot Product Development 2MonoSol Rx Completes Thin Film Escitalopram Oxalate Pilot Product Development 3
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... According to the article published ... of the Pasadena courthouse was contained and extinguished by the city’s fire department before it ... the building at the time of the fire, and it was a fire alarm system ...
(Date:7/31/2015)... ... July 31, 2015 , ... Well-known for its unique pastries and ... cakes with custom designs, making life just a little bit sweeter for newlyweds. ... for each customer who orders one. , The bakery provides a full line of ...
(Date:7/31/2015)... ... , ... Cosmetic Town has proven itself as the leader ... procedures including, but not limited to, abdominoplasty, blepharoplasty, rhinoplasty and septoplasty. The ... , Staying up to date with the latest cosmetic trends has never ...
(Date:7/31/2015)... ... July 31, 2015 , ... The 2015 New York ... family members, medical professionals, and researchers, covering a variety of topics related to ... collaborative effort between the Mesothelioma Applied Research Foundation and Memorial Sloan Kettering Cancer ...
(Date:7/31/2015)... ... July 31, 2015 , ... Creating one of the ... in pursuit of a visionary image that goes beyond the boundaries of fertility medicine. ... IVF has reached extraordinary heights with dependable patient support, affordable treatments, unending hope, and ...
Breaking Medicine News(10 mins):Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 3Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2Health News:Cosmetic Town: Now Providing Interactive And Vital Medical Knowledge 2Health News:New York Area Mesothelioma Specialists to Present at Conference 2Health News:New York Area Mesothelioma Specialists to Present at Conference 3Health News:New Hope IVF Now Offers Most Affordable Assisted Reproductive Treatment in the UAE 2Health News:New Hope IVF Now Offers Most Affordable Assisted Reproductive Treatment in the UAE 3
... LINTHICUM, MD. The AUA is pleased to announce their ... Cancer. Each year, more than 60,000 people are diagnosed ... number of risk factors, including cigarette smoking and exposure ... in 1999 and the report issued today is an ...
... universal hepatitis B immunisation means that most UK citizens ... in this weeks BMJ. , The UK is one ... routinely immunise children against hepatitis B, despite a call ... of vaccine prevention programmes by 1997, writes Andrew Pollard, ...
... binge drinking in the UK rise, doctors in this weeks ... attended hospital with lower abdominal pain. , Although rare, this ... alcohol intake. , Alcohol misuse is costing the NHS up ... by alcohol dependence or poisoning and 22,000 premature deaths each ...
... settlement as ,the ... right thing to do, HOUSTON, Nov. ... agreement with pharmaceutical giant,Merck & Co. Inc. (NYSE: MRK ) that ... over Vioxx, the company,s,controversial pain medication. (Photo: http://www.newscom.com/cgi-bin/prnh/20060623/DAF008 ) ...
... Provides Preliminary Information on Recapitalizations, Asset Sales and ... Anticipated Pre-Tax Charges ... on Accounting Restatement, MCLEAN, Va., Nov. 9 Sunrise Senior Living,Inc. ... the quarter ended September 30, 2007. The Company also,provided preliminary information on ...
... Client Development Officer, SOMERSET, N.J., Nov. 9 ... it has created a new Client Development,and Integration team. ... was recently,promoted to Chief Client Development Officer. The ... across the company,s segments to identify new opportunities to,serve ...
Cached Medicine News:Health News:AUA releases new guidelines on non-muscle invasive bladder cancer 2Health News:Most UK citizens susceptible to hepatitis B infection 2Health News:The Lanier Law Firm Announces $4.85 Billion National Vioxx Settlement With Merck & Co. Inc. 2Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 2Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 3Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 4Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 5Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 6Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 7Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 8Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 9Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 10Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 11Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 12Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 13Health News:inVentiv Health Creates Client Development and Integration Team 2Health News:inVentiv Health Creates Client Development and Integration Team 3
A finely parallel striated (scratched) clear plastic membrane encapsulated between glass plates....
BD Visitec IOL Manipulator, blunt tip, formed 10.0mm from end. Fits 0.20mm diameter holes & larger (3/bx, 1 bx/ca). For positioning intraocular lenses. Sure grip handles hand ridge indicating positio...
BD Visitec IOL Manipulator (Lester), 0.25 mm diameter tip angled 45 in, 10 mm from end (3/bx, 1 bx/ca), sterile. For positioning intraocular lenses. Sure grip handles hand ridge indicating position o...
Lewicky lens manipulator. Also available in titanium....
Medicine Products: